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Aspirin gained tremendous popularity during the
1918 Spanish Influenza virus pandemic, 50 years
prior to the demonstration of their inhibitory action
on prostaglandins. Here, we show that during
influenza A virus (IAV) infection, prostaglandin E2
(PGE2) was upregulated, which led to the inhibition
of type I interferon (IFN) production and apoptosis
in macrophages, thereby causing an increase in
virus replication. This inhibitory role of PGE2 was
not limited to innate immunity, because both antigen
presentation and T cell mediated immunity were also
suppressed. Targeted PGE2 suppression via genetic
ablation of microsomal prostaglandin E-synthase 1
(mPGES-1) or by the pharmacological inhibition of
PGE2 receptors EP2 and EP4 substantially improved
survival against lethal IAV infection whereas PGE2
administration reversed this phenotype. These data
demonstrate that the mPGES-1-PGE2 pathway is
targeted by IAV to evade host type I IFN-dependent
antiviral immunity. We propose that specific inhibi-
tion of PGE2 signaling might serve as a treatment
for IAV.
INTRODUCTION
The lung innate immune system has a critical role in limiting
respiratory viral infections (Braciale et al., 2012). Alveolar macro-
phages (M4) are one of the first immune cells to encounter pul-
monary viruses and are indispensable for several key antiviral
mechanisms including: (1) virus recognition and initiation of
cytokine and chemokine production, (2) instruction of adaptive554 Immunity 40, 554–568, April 17, 2014 ª2014 Elsevier Inc.immunity, and (3) control of lung injury and resolution of inflam-
mation (Kim et al., 2008; Shirey et al., 2010). Initially, upon
sensing viral pathogen-associated molecular patterns (PAMPs),
macrophages induce a cascade of cytokine responses including
type I interferon a (IFN-a) and IFN-b production. Type I IFNs
signal through the IFN-a receptor (IFNAR) and induce the upre-
gulation of numerous genes that activate both innate and adap-
tive immunity for rapidly controlling viral replication (Koerner
et al., 2007). In addition, infected macrophages might undergo
apoptosis to restrict viral dissemination (Mok et al., 2007) and
to enhance T cell-mediated immunity via antigen (Ag) cross-pre-
sentation (Albert et al., 1998). Recent evidence also suggests
that during infection, macrophages have the capacity to trans-
port Ags from the lung to the draining lymph nodes and poten-
tially contribute to the induction of adaptive immune responses
(Kirby et al., 2009).
Although cytokines have been extensively studied in the
context of viral infection, little is known about the function of the
prostanoid (which includes prostaglandins [PG]) in antiviral im-
munity (McCarthy and Weinberg, 2012). Among PGs, PGE2 is
the best-characterized immune modulatory lipid, acting on four
subtypes of G protein-coupled E prostanoid receptors (EP1-
EP4) to exert both pro- and anti-inflammatory responses de-
pending on the source of inflammation (Ricciotti and FitzGerald,
2011). Biologically active PGE2 originates fromPGH2,which itself
is the product of cyclooxygenase-1 (COX-1) and COX-2-medi-
ated enzymatic conversion of membrane phospholipid-derived
arachidonic acid (AA) (Figure 1A). Whereas three enzymes have
been shown to independently generate PGE2 from PGH2 (Smyth
et al., 2009), microsomal prostaglandin E-synthase 1 (mPGES-1)
is the dominant isoform for PGE2 synthesis in different mouse
models of inflammation especially involving macrophages
(Hara et al., 2010). Aspirin, a COX inhibitor, gained popularity
during the 1918 Spanish Influenza A virus (IAV) pandemic
(Starko, 2009) and has since then been used for the manage-
ment of IAV symptoms. However, the loss-of-function in COX
Figure 1. Ptges–/– Mice Have More Monocytes and Macrophages and Are More Protected against IAV Infection
(A) Schematic representation of prostanoid synthesis pathways. Membrane phospholipid-derived AA is converted to PGH2 by COX-1 and COX-2. PGH2 is then
converted by specific synthases to five major bioactive prostanoids. Highlighted in red is the specific pathway leading to the formation of PGE2 by PGES
enzymes, of which mPGES-1 is the dominant isoform.
(B–O) WT and Ptges/ mice were infected with a sublethal dose (50 PFU) (B–D and F–O) or a lethal dose (150 PFU) (E) of IAV. Plasma (B) and BAL (C) PGE2
concentrations and pulmonary viral loads (D and E) were measured p.i. (F and G) Micrographs of H&E-stained lung sections prepared p.i. and representative of
the inflammation score depicted in (G). (H) Total lung resistance was measured upon methacholine challenge at day 12 p.i. with flexiVent. Data are presented as
fold increases in pulmonary resistance relative to baseline resistance measured prior to methacholine challenge. (I and J) Fold increase in type I IFN (a and b) (I) or
IFN-b (J) secretion in the lungs (left panels) and BAL (right panels) at day 3 p.i. was measured by B16-Blue reporter cells or ELISA. (K) Chemokines from pooled
BAL of infected mice at day 3 p.i. evaluated with a cytokine array. (L and M) Frequency of monocytes (Mono, CD11cF4/80CD115+) and macrophage (lungs:
CD11c+F4/80+ and CD11cF4/80+; BAL: CD11c+F4/80+) in the lungs and BAL. (N and O) Total numbers of Mono and macrophages, neutrophils (Neutro,
CD11cF4/80CD115Gr1+), NK cells (CD19NK1.1+), and T cells (CD19CD3+) in the lungs and BAL at day 3 p.i. (n = 3–5; ± SEM). Results are representative of
at least three independent experiments. In (H), *p < 0.05, ***p < 0.0001 versus WT uninfected controls (two-way ANOVA) and +p < 0.05 versus infected Ptges/
mice. In all other panels, *p < 0.05, **p < 0.001, ***p < 0.0001 versus the other genotype. See also Figure S1.
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Figure 2. PGE2 Inhibits Type I IFN Production and Apoptosis by Macrophages
(A–K)WT and/or Ptges/BMDMwere infected or not with IAV. (A) Fold induction in IfnbmRNA and (B) IFN-b secretion weremeasuredwith qRT-PCR and ELISA.
(C) Cell death ELISA at 24 hr p.i. (D) Fold increase in apoptotic blebs formation relative to uninfected or unstimulated cells at 24 hr p.i. (E and F) Fold induction in
Ep1, Ep2, Ep3, and Ep4 mRNA in WT (E) and Ptges/ (F) BMDM were measured by qRT-PCR. (G) Ptges/ BMDM were pretreated or not with various
combinations of PGE2, EP2 antagonist, EP4 antagonist, PI3K-Akt inhibitor, or PKA inhibitor for 1 hr and then infected or not for 24 hr. Fold increase in type I IFN
(a and b) (top panel) and apoptosis (bottom panel) relative to uninfected and unstimulated cells were measured. (H) pIRF3 and total IRF3 proteins were measured
in whole-cell protein extracts of WT and Ptges/ BMDM. Macrophages were pretreated or not with PGE2 for 1 hr prior to IAV infection (5 MOI) or stimulated with
1 mg/ml LPS. Actin was used as a loading control. Densitometry analysis (bottom) of pIRF3 was relative to IRF3 expression. (I and J) BMDMwere pretreated or not
with various concentrations of PGE2 for 1 hr and then infected for 24 hr. Fold increase in type I IFN secretion (I) and viral load (J) was measured. (K) Ptges
/
BMDM were pretreated or not with PGE2, PGD2, PGF2a, PGI2, or carbocyclic TXA2 for 1 hr, infected for 24 hr, and viral load was then measured.
(legend continued on next page)
Immunity
PGE2 Inhibition Enhances Antiviral Immunity
556 Immunity 40, 554–568, April 17, 2014 ª2014 Elsevier Inc.
Immunity
PGE2 Inhibition Enhances Antiviral Immunityproteins have yielded controversial findings upon IAV infection
(McCarthy and Weinberg, 2012) potentially due to inhibition of
all PGs including PGE2, PGI2, PGD2, PGF2a, and thromboxane
A2 (TXA2).
We have previously shown that Mycobacterium tuberculosis
(Mtb) inhibits PGE2 production in macrophages to suppress
both innate and adaptive immunity (Chen et al., 2008; Divan-
gahi et al., 2009; Divangahi et al., 2010) and, therefore,
mPGES-1-deficient (Ptges/) mice, which specifically lack
PGE2, are highly susceptible to infection. In sharp contrast to
Mtb infection, we herein report that Ptges/ mice demon-
strated remarkably enhanced protection against IAV infection.
Mechanistically, PGE2 acted via macrophage EP2 and EP4 re-
ceptors to inhibit type I IFN production and apoptosis, thereby
directly impairing the capacity of mouse and human macro-
phages, but not epithelial cells, to restrict viral replication.
T cell recruitment and Ag-specific T cell response were also
enhanced in infected Ptges/ mice. Finally, we show that
treatment with a specific mPGES-1 inhibitor drastically reduced
the mortality rate of mice lethally infected with IAV in a type I
IFN manner.
RESULTS
Ptges–/– Mice Are More Resistant to IAV Infection and
Promote Monocyte and Macrophage Recruitment into
the Lungs
To assess whether there is an alteration in PGE2 during the
course of IAV infection in vivo, we first measured PGE2 amounts
in plasma and bronchoalveolar lavage (BAL) fluid of IAV-infected
mice. IAV infection markedly increased PGE2 in WT mice,
whereas such increase was blunted in Ptges/ mice as ex-
pected (Figures 1B and 1C). Interestingly, increased PGE2
was associated with higher viral loads in the lungs of WT mice
at day 3 and 6 postinfection (p.i.) as compared to Ptges/
mice (Figures 1D and 1E). Lung histological analysis showed
an increase in inflammation in Ptges/ mice during the early
phase of infection while inflammation gradually and similarly
increased from day 3 to day 9 in both WT and Ptges/ mice
with a trend to be reduced in the lungs of Ptges/ mice at
day 12 p.i. (Figures 1F–1G; see also Figure S1A available
online). We next evaluated the consequences of inflammation
on lung physiology. Although no significant difference was
observed between groups at day 6 p.i. (Figure S1B), airway hy-
perreactivity (AHR) was reduced in IAV-infected Ptges/mice
at 12 days p.i. (Figure 1H; Figure S1C), which was in line with
faster resolution of inflammation in these mice. The improve-
ment of AHR in IAV-infected Ptges/ mice was associated
with substantial reduction of interleukin-13 (IL-13) in the lungs,
a key cytokine involved in mediating AHR (Chang et al., 2011)
(Figure S1D).
In order to investigate whether the early increase in inflam-
mation at day 3 was consistent with the protective phenotype(L–N) WT and/or Ptges/ BMDM were infected or stimulated or not with IAV (MO
increase in type I IFN (a and b) secretion wasmeasured (L). (M) Fold induction in Pt
measured at 4 hr following infection or stimulation with ELISA. Results are ± SEM a
***p < 0.0001: in (A–D and L), versus WT; in (E–G and N), versus uninfected or
unstimulated BMDM of the same genotype unless indicated otherwise (two-wayof IAV-infected Ptges/ mice, we next characterized the innate
immune response in wild-type (WT) and Ptges/ mice after IAV
infection. Measurement of pulmonary cytokine and chemokine
responses revealed increases in type I IFN-a and IFN-b as well
as IL-12p40 in the lungs of Ptges/ mice compared to WT
animals at day 3 p.i. (Figures 1I and 1J; Figure S1E). In addition,
monocyte chemotactic protein-1 (MCP-1) and MCP-5, impli-
cated in monocyte recruitment during IAV infection (Dessing
et al., 2007; Sarafi et al., 1997), but not chemokine (C-X-C
motif) ligand 1 (CXCL1), which is mainly involved in neutrophil
recruitment (Wareing et al., 2007), were markedly increased in
the BAL of Ptges/ mice (Figure 1K). Consistent with the che-
mokine profile, we observed a transient increase in the fre-
quency of monocytes and macrophages at day 3 p.i. in both
the lungs and the BAL of Ptges/ mice compared to WT
mice (Figures 1L and 1M; Figures S1F and S1G). This increase
was specific to monocytes, macrophages, and dendritic cells
(DCs) because only the number of these cells, but not neutro-
phils, natural killer (NK) cells, and T cells, were increased in
both the lungs and the BAL of Ptges/ mice (Figures 1N and
1O; Figures S1F–S1L). The increased pool of monocytes and
macrophages recruited to the lungs of Ptges/ mice might
have, at least in part, originated from blood-derived monocytes
as previously described (Landsman and Jung, 2007) since the
number of monocytes, but not neutrophils or NK cells, was
transiently increased in the blood circulation at day 1 p.i. (Fig-
ures S1M–S1O). Collectively, these results suggest that PGE2
plays an opposing role in immune protection against IAV infec-
tion by suppressing monocytes and macrophage recruitment
into the lungs.
PGE2-Deficient Macrophages Have Enhanced Antiviral
Activity against IAV Infection
Because macrophages are essential for pulmonary antiviral
immunity by producing type I IFN and undergoing apoptosis
to restrict IAV dissemination (Kim et al., 2008; Mok et al.,
2007; Xing et al., 2009), we next examined the effect of PGE2
on macrophage-mediated immunity to IAV infection. Interest-
ingly, bone-marrow-derived macrophages (BMDM) obtained
from Ptges/ mice produced more IFN-b than WT macro-
phages upon IAV infection (Figures 2A and 2B). Strikingly,
Ptges/ macrophages infected with IAV underwent increased
apoptosis and produced considerably more apoptotic vesicles
than WT macrophages (Figures 2C and 2D), whereas exoge-
nous PGE2 suppressed apoptosis in IAV-infected THP-1 mac-
rophages (Figure S2A). Following in vivo infection, macrophage
apoptosis but not necrosis was also increased in the lungs of
Ptges/ mice relative to WT mice (Figure S2B). To determine
the mechanism(s) by which PGE2 inhibits macrophage type I
IFN production and apoptosis following IAV infection, we
first measured the expression of mRNA encoding mPGES-1
and PGE2 receptors EP1-4 in infected WT and Ptges
/
macrophages by using quantitative RT-PCR. IAV infectionI = 1) of UV-inactivated IAV, 50pppRNA (1 mg/ml), or PolyI:C (1 mg/ml) and fold
gesmRNA inWT BMDMwasmeasured with qRT-PCR. (N) PGE2 secretion was
nd are representative of three independent experiments. *p < 0.05, **p < 0.001,
unstimulated BMDM (two-way ANOVA); in (I–K and M), versus infected but
ANOVA). See also Figure S2.
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coding mPGES-1, EP2, and EP4, but not EP1, and EP3 in
WT, but not Ptges/ macrophages (Figures 2E and 2F; Fig-
ure S2C). We next used antagonists for EP2 and EP4, as well
as inhibitors of their downstream signaling kinases phosphoti-
dylinositol-3 kinase (PI3K), Akt, and protein kinase A (PKA) (Re-
gan, 2003), to determine the specific pathway(s) through which
PGE2 inhibited type I IFN secretion and apoptosis. Reconstitu-
tion of PGE2 in IAV-infected Ptges
/ macrophages reduced
both type I IFN secretion (Figure 2G, upper panel) and
apoptosis (Figure 2G, lower panel). Inhibition of EP2, EP4, or
both EP2 and EP4 in IAV-infected Ptges/ macrophages
exposed to PGE2 restored type I IFN induction indicating that
both EP2 and EP4 are the major PGE2 receptors responsible
for inhibition of type I IFN (Figure 2G, upper panel). We further-
more confirmed that downstream signaling kinases PI3K-Akt as
well as PKA are involved in mediating the inhibitory effects of
PGE2 on type I IFN production (Figure 2G, upper panel). How-
ever, during apoptosis, the inhibitory action of PGE2 was
dependent only on EP2 and PKA but not EP4 and PI3K-Akt
in IAV-infected Ptges/ macrophages (Figure 2G, lower panel).
We next evaluated the phosphorylation of the IRF3 (pIRF3),
which is a key transcription factor for induction of type I IFN
in IAV-infected cells. Ptges/ macrophages exhibited an early
increase in pIRF3 as compared to WT macrophages following
IAV infection (Figure 2H). Importantly, PGE2 reconstitution in
Ptges/ macrophages drastically inhibited pIRF3 following
IAV infection. Consistent with the inhibitory effects of PGE2
on IRF3-mediated type I IFN signaling, Ptges/ macrophages
showed increased type I IFN and decreased viral load, while
addition of exogenous PGE2 in a dose-dependent manner
reduced type I IFN and enhanced viral replication in both WT
and Ptges/ macrophages (Figures 2I and 2J). Unlike PGE2,
addition of other prostanoids (PGD2, PGF2a, PGI2, TXA2) to
IAV-infected Ptges/ macrophages had no effect on viral repli-
cation (Figure 2K; Figure S2D). Moreover, selective antagonists
for individual PG receptors showed no changes in either type I
IFN production or viral load in IAV-infected Ptges/ macro-
phages (Figure S2E). These data collectively rule out the possi-
bility that, in the absence of mPGES-1, PGH2 is converted to
other PGs that then contribute to antiviral immunity. Further-
more, similar to another report (Trebino et al., 2005) demon-
strating that in the absence of mPGES-1 there is no shunting
to the leukotriene pathway, we also found no difference in
kinetics of leukotriene B4 production in either plasma or BAL
of IAV-infected WT and Ptges/ mice (Figures S2F and
S2G). To further dissect the mechanism of how IAV inhibits
type I IFN via PGE2 in macrophages, we stimulated WT and
Ptges/ macrophages with UV-treated replication-deficient
IAV or the RIG-I ligands 50pppRNA and PolyI:C. Under these
conditions, mPGES-1-dependent type I IFN production was
abolished indicating that active viral replication is required for
IAV to inhibit type I IFN via PGE2 (Figure 2L; Figures S2H–
S2J). Consistent with this observation, replication-competent
IAV induced more mRNA encoding mPGES-1 than UV IAV or
RIG-I ligands and only the replication competent virus induced
PGE2 secretion in WT macrophages (Figures 2M and 2N).
These data collectively indicate that IAV specifically targets
the mPGES-1 pathway and that PGE2 was the main mediator558 Immunity 40, 554–568, April 17, 2014 ª2014 Elsevier Inc.inhibiting macrophage type I IFN-dependent antiviral immunity
to IAV infection.
Considering BMDM are not an ideal representative of pulmo-
nary macrophages, we next extended our study to investigate
the potential role of PGE2 in alveolar macrophages (AM) in-
fected with IAV. Similar to BMDM, Ptges/ AM had increased
type I IFN and decreased viral titer as compared to WT AM
(Figures 3A and 3B). Pretreatment of AM of both genotypes
with exogenous PGE2 decreased type I IFN and increased viral
load (Figures 3A and 3B). Supporting these findings, intracel-
lular staining of AM with an antibody against IAV nucleoprotein
(NP) revealed that PGE2 deficiency decreased the frequency of
infected AM (Figure 3C), whereas exogenous PGE2 increased
the frequency of both infected WT and Ptges/ AM. A similar
result was obtained with BMDM (data not shown). Importantly,
in human macrophages infected with a clinical strain of IAV,
gene targeting of mPGES-1 with small interfering RNA (Fig-
ure 3D) or administration of exogenous PGE2 (Figure 3E; Fig-
ure S3A) confirmed the detrimental role of the PGE2 pathway
in the control of viral replication and recapitulated our findings
in murine macrophages. To directly test whether the increased
antiviral activity of Ptges/ macrophages translated to a better
control of IAV infection in vivo, AM derived from WT and
Ptges/ mice were infected with IAV in vitro and adoptively
transferred intratracheally (i.t.) to Rag1/ mice (lacking T and
B cells) (Figure 3F). Although both the frequency of infected
cells and the number of viruses in WT and Ptges/ macro-
phages was similar prior to transfer (Figures S3B and S3C),
the mice that received infected Ptges/ macrophages showed
increased type I IFN (Figure 3G; Figure S3C) and decreased
pulmonary viral titer (Figure 3H) as compared to the mice
receiving infected WT macrophages. To further support this
observation, we next adoptively transferred (i.t.) either naive
WT or Ptges/ macrophages into naive WT recipient mice.
Then after adoptive transfer, mice were infected with IAV. Simi-
larly, adoptive transfer of Ptges/ macrophages into WT recip-
ients led to increased type I IFN production, decreased viral
replication and increased survival (Figures 3I–3L; Figure S3E).
Because PGE2 inhibited the production of type I IFN in IAV-
infected macrophages, we hypothesized that the ability of a
specific murine mPGES-1 inhibitor (CAY10526) to limit viral
replication is directly linked to the type I IFN system. To test
this hypothesis, we first assessed the capacity of the
mPGES-1 inhibitor to reduce viral replication in WT macro-
phages, Ptges/ macrophages, and in macrophages lacking
the type I IFN receptor (Ifnar/), which are unable to respond
to type I IFN. As expected, Ptges/ macrophages infected
with IAV revealed a reduction in viral load, whereas Ifnar/
macrophages showed increased viral load in comparison to
IAV-infected WT macrophages (Figure 3M). The mPGES-1 in-
hibitor reduced viral load in IAV-infected WT macrophages to a
similar level as in IAV-infected Ptges/ macrophages but had
no effect in Ptges/ macrophages. Importantly, the protective
effect of the mPGES-1 inhibitor in controlling viral replication
was completely abrogated in Ifnar/macrophages (Figure 3M).
We next considered whether neutralizing antibodies (Abs)
against both IFN-a and IFN-b would recapitulate the phenotype
of Ifnar/ macrophages infected with IAV. Treatment of IAV-in-
fected macrophages with neutralizing Abs against both IFN-a
Figure 3. PGE2 Impairs the Control of Viral Replication by Macrophages via Type I IFN
(A–C) AM from naive WT and Ptges/ mice were pretreated or not with PGE2 for 1 hr and infected or not with IAV. IFN-b secretion (A) and viral load (B) were
measured from the supernatant at 24 hr p.i. (C) Kinetics of the frequency of infected AM (CD11c+F4/80+NP+). Zebra plots are representative of the 24 hr time-point
and numbers adjacent to gates indicate percent of macrophages stained with intracellular anti-NP.
(D) Viral load in the supernatant of THP-1 cells transfected with a noncoding sequence transfection control (NC1) ormPGES-1-targetting DsiRNA and infected for
24 hr with IAV H3N2. Immunoblot analysis of mPGES-1 gene silencing in THP-1 macrophages is shown.
(E) Viral load in the supernatant of primary human macrophages pretreated or not with PGE2 for 1 hr and infected for 24 hr with IAV H3N2.
(F–H) AM from naive WT and Ptges/ mice were isolated and infected with IAV in vitro and then adoptively transferred (i.t.) to Rag1/ mice (n = 5). IFN-b
concentration (G) and viral loads (H) were measured in the lungs of Rag1/ mice 3 days after adoptive transfer.
(I–L) BMDM fromWT and Ptges/mice were adoptively transferred (i.t.) toWTmice, which were then infected with IAV after 2 hr (n = 5–10). Fold increase in type I
IFN (a and b) (J), viral loads (K), and survival (L) were assessed 3 days after adoptive transfer.
(M and N) WT, Ptges/, and Ifnar/BMDMwere treated or not with a specific murine mPGES-1 inhibitor and/or anti-IFN-a and anti-IFN-b and infected with IAV.
Viral load was measured 24 hr p.i. Results are shown as means ± SEM and are representative of at least two independent experiments. *p < 0.05, **p < 0.001,
***p < 0.0001. In (C), (two-way ANOVA). See also Figure S3.
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mPGES-1 inhibitor and Ptges deletion on viral replication (Fig-
ure 3N). Therefore, IAV infection specifically activates the PGE2pathway in macrophages to inhibit type I IFN and apoptosis
through EP2 and EP4-dependent mechanisms, thereby impair-
ing macrophage capacity to restrict viral replication.Immunity 40, 554–568, April 17, 2014 ª2014 Elsevier Inc. 559
Figure 4. PGE2 Does Not Directly Impair Antiviral Immunity in Airway Epithelial Cells
(A) BMDM andmouse primary airway epithelial cells derived fromWTmice were infected or not with IAV for 24 hr to assess PtgesmRNA expression by qRT-PCR.
*p < 0.05 versus IAV-infected WT epithelial cells.
(B and C)WT and Ptges/micewere administered control liposomes or clodronate liposomes to deplete alveolar phagocytes prior to infection with IAV (50 PFU,
n = 5 mice per group). (B) Representative dot blots depicting the analysis of the frequency of AM in PBS-treated WT mice or liposome-treated WT and Ptges/
mice at day 3 p.i. Numbers adjacent to gate indicate percent of AM. (C) Viral loadwasmeasured in the lungs of control liposome- and clodronate liposome-treated
mice at day 3 pi. *p < 0.05, **p < 0.001. Data are representative of three independent experiments.
(D–G) WT and Ptges/ murine primary airway epithelial cells were infected or not with IAV as in (A) to assess Ifnb (D) or Ifna4 (E) mRNA by qRT-PCR, IFN-b
secretion (F) by ELISA, and viral load (G).
(H–K)Murine epithelial (MLE12) cells were infected or not with IAV as in (A) in the presence or absence of exogenous PGE2 or themPGES-1 inhibitor to assess Ifnb
mRNA by qRT-PCR (H), type I IFN (a and b) secretion using B16 cells (I and J), and viral load at 24 hr p.i. (K).
(legend continued on next page)
Immunity
PGE2 Inhibition Enhances Antiviral Immunity
560 Immunity 40, 554–568, April 17, 2014 ª2014 Elsevier Inc.
Immunity
PGE2 Inhibition Enhances Antiviral ImmunityAntiviral Immunity of Airway Epithelial Cells Is Not
Directly Affected by PGE2
Airway epithelial cells are known to constitutively secrete PGE2
and to contribute to the modulation of DCs under homeostatic
conditions (Schmidt et al., 2011). To investigate the potential
contribution of epithelial cells as a source of PGE2, we purified
CD45CD326+ primary airway epithelial cells from WT and
Ptges/ mice (Figure S4A). Initially, we measured the induction
of mRNA encoding mPGES-1 by IAV infection in epithelial cells
derived from WT mice and found that its induction was almost
negligible relative to macrophages (4.0-fold ± 0.6 SEM versus
42.4-fold ± 5.6 SEM, Figure 4A). To further investigate the poten-
tial contribution of PGE2-dependent macrophage immunity to
IAV infection, we next depleted alveolar phagocytes from WT
andPtges/mice prior to IAV infection by using clodronate lipo-
somes. Similar to other studies (Huang et al., 2011), 75% AM
were depleted prior to infection (data not shown) and these cells
were reduced by 50% at day 3 p.i. (Figure 4B). As expected,
Ptges/ mice treated with control liposomes had lower viral
load in the lungs compared to control liposome-treated WT
mice (Figure 4C). Macrophage depletion increased viral replica-
tion in bothWT andPtges/ lungs. Importantly, the level of repli-
cation in macrophage-depleted Ptges/mice was similar to the
levels of viral replication in macrophage-competent WT mice,
suggesting that the ability of Ptges/ mice to restrict viral repli-
cation is mediated by macrophages and not other cell types,
especially pulmonary epithelial cells. In addition, there was no
difference in type I IFN expression or viral load between IAV-in-
fected WT and Ptges/ mouse primary airway epithelial cells
(Figures 4D–4G) and between mouse (Figures 4H–4K; Figures
S4B–S4D) or human (Figures 4L–4O) airway epithelial cell lines
treated or not with exogenous PGE2 or the mPGES-1 inhibitor.
Furthermore, the loss of mPGES-1 function in primary human
bronchial epithelial cells had no effect on viral load (Figure 4P).
Thus, although the constitutive production of PGE2 by the airway
epitheliummight contribute to the inhibition of macrophage anti-
viral activity through a paracrine pathway, it does not directly
affect type I IFN or viral replication in epithelial cells.
PGE2 Inhibits T Cell Recruitment and Delays the Onset
of IAV Ag-Specific T Cell Response in the Lungs
Macrophage apoptosis provides an important link to adaptive
immunity as viral Ag contained in apoptotic vesicles can be taken
up by DCs and efficiently presented to naive T cells leading to
generation and maintenance of protective virus-specific T cell
responses (Albert et al., 1998). Because IAV-infected Ptges/
macrophages revealed increased apoptosis and apoptotic ves-
icles, we next examined the generation and kinetics of T cell
mediated immunity in WT and Ptges/mice following IAV infec-
tion. The total T cell numbers as well as CD4+ and CD8+ T cells
were increased in the mediastinal lymph nodes (LN) (Figures
S5A andS5C), BAL (Figure 5A; Figure S5C), and lungs (Figure 5B;
Figures S5B and S5C) of Ptges/mice compared to WT. This is(L–O) Human epithelial (A549) cells were infected or not with IAV H3N2 in the pres
expression. The frequency of infected cells was evaluated by intracellular stainin
(P) Viral load in human bronchial epithelial cells (NHBE) transfected with a nonco
infected for 24 hr with IAV H3N2. Immunoblot analysis ofmPGES-1 gene silencing
and are representative of three independent experiments. See also Figure S4.consistent with an increase in pulmonary CXCL9 and CXCL10,
chemokines implicated in T cell recruitment during IAV infection
(Piqueras et al., 2006) (Figure S5D). Additionally, the Ag-specific
CD8+ T cell response to the immunodominant NP Ag was higher
in the BAL (Figure 5C) and lungs (Figures 5D and 5E) of Ptges/
mice. Pulmonary T cells from infected Ptges/ mice produced
more IFN-g after being stimulated with whole UV-inactivated
IAV, NP peptide (specific for CD8+ T cells) or hemagglutinin
(HA) peptide (specific for CD4+ T cells) than did T cells from in-
fected WT mice (Figures 5F and 5G). Consistent with the
increased frequency of IFN-g-secreting CD4+ T cells in Ptges/
mice and with the previous finding that PGE2 negatively regu-
lates MHC class II expression in macrophages (Zaslona et al.,
2012), the surface expression of MHC class II was increased in
Ptges/ compared to WT macrophages following IAV infection
(Figure S5E).
Because the increased T cell response in Ptges/ mice was
not due to enhanced intrinsic capacity of T cells to proliferate
as assessed by an in vitro assay of T cell proliferation (Fig-
ure S6A), we next determined whether PGE2 directly inhibits
Ag presentation during IAV infection in a type I IFN-dependent
manner. WT, Ptges/, and Ifnar/ macrophages were pre-
loaded with ovalbumin (OVA) and cocultured with CFSE-labeled
OVA-specific CD8+ T cells derived from OT-I mice (TCR-trans-
genic CD8+ T cells specific for the OVA SIINFEKL epitope) in
the presence or absence of IAV infection and/or themPGES-1 in-
hibitor. In the absence of infection, WT, Ptges/, and Ifnar/
macrophages loaded with OVA induced similar levels of OT-I
CD8+ T cell proliferation whether themPGES-1 inhibitor was pre-
sent or not (Figures 6A and 6B). However, in the presence of IAV
infection, the proliferation of OT-I CD8+ T cells was reduced in
WT and Ifnar/ macrophages compared to Ptges/ macro-
phages. Similarly, addition of the mPGES-1 inhibitor to IAV-
infected WT macrophages restored their ability to induce OT-I
CD8+ T cell proliferation up to a similar level to Ptges/ macro-
phages. Importantly and consistent with the notion that type I
IFN are known to enhance cross-presentation (Le Bon and
Tough, 2008), the effect of the mPGES-1 inhibitor in enhancing
OT-I CD8+ T cell proliferation was absent in Ifnar/ macro-
phages. Therefore, these data collectively indicate that PGE2
suppresses antiviral T cell-mediated immunity by dampening
both cross- and direct priming of T cells via inhibition of the
type I IFN system during IAV infection.
To investigate whether the enhanced T cell response in
Ptges/mice was due to an intrinsic property of Ptges/mac-
rophages, AM derived fromWT and Ptges/mice were infected
with IAV in vitro and adoptively transferred (i.t.) into WT recipient
mice (Figure 6C). Although the number of viruses in WT and
Ptges/macrophages was similar prior to transfer (Figure S6B),
the WT mice that received IAV-infected Ptges/ macrophages
showed increased frequency and absolute number of Ag-spe-
cific CD8+ T cells in the mediastinal LN (Figure 6D), as well as
decreased pulmonary viral titer at day 7 posttransfer (Figure 6E).ence or absence of exogenous PGE2 to assess Ifnb (L) and Ifna PAN (M) mRNA
g with anti-NP (N), and viral load was determined (O).
ding sequence transfection control (NC1) or mPGES-1-targetting DsiRNA and
in NHBE cells infected with IAV is shown. Results are shown as means ± SEM
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Figure 5. Ptges–/– Mice Have Enhanced T Cell Mediated Immunity to IAV Infection
(A–G)WT and Ptges/mice were infected with a sublethal dose of IAV. Kinetics of total T cell (CD19CD3+) numbers in the BAL (A) and lungs (B) were evaluated.
(C–E) Kinetics of the frequency of IAV H-2Db-NP CD8+ T cells wasmeasured in the BAL (C) and lungs (D and E). Numbers adjacent to gates indicate percent CD8+
T cells stained with the NP-loaded H-2Db tetramer (NPTet). (F and G) The frequency of Ag-specific IFN-g-releasing T cells from lungs or BAL was determined
following 10 hr stimulation with UV-inactivated IAV (1MOI) or 5 mg/ml IAVNP366–374 or IAVHA110–120 peptides by intracellular cytokine staining and flow cytometry.
(F) Representative dot blots depicting the analysis of frequency of IAV NP366–374-specific IFN-g-secreting CD8
+ T cells in the lungs of IAV-infected WT and
Ptges/mice at day 11 pi. Numbers adjacent to gates indicate percent IFN-g-secreting CD8+ T cells following ex vivo restimulation with MHC class I-restricted
IAV NP366–374 peptide. (G) Total number of CD8
+ (left panels) and CD4+ (right panels) IFN-g-secreting T cells specific for either UV-inactivated IAV or MHC class
I-restricted NP366–374 and MHC class II-restricted HA110–120 peptide respectively in the lungs (top panels) and BAL (bottom panels) of IAV-infected WT and
Ptges/ mice at day 9 and 11 p.i. (n = 3–5; ± SEM). Results are representative of three independent experiments. *p < 0.05 versus WT. See also Figure S5.
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macrophages survived, whereas 80% of mice receiving IAV-in-
fected WT macrophages succumbed to death by day 9 post-
transfer (Figure 6F). Thus, the absence of PGE2 production in
IAV-infected Ptges/ macrophages correlates with greater
T cell response, enhanced protection, and survival during infec-
tion in vivo.
Because PGE2 negatively regulated both the innate and adap-
tive arms of immunity to IAV infection, we next delineated the
contributions of each arm to protection against lethal IAV infec-
tion. Initially, we used monoclonal antibodies (Abs) to deplete
CD4+ and CD8+ T cells in WT and Ptges/ mice (Figure S6C).
WTmice depleted or not of T cells all died within 10 days of infec-
tion (Figure 6G; Figure S6D). Although Ptges/mice depleted of
T cells had increased susceptibility relative to their T cell-compe-
tent Ptges/ counterparts, they still demonstrated improved562 Immunity 40, 554–568, April 17, 2014 ª2014 Elsevier Inc.survival over WT mice. Moreover, pharmacological inhibition of
mPGES-1 in Rag1/ mice again caused an increase in survival
against lethal IAV challenge (Figure 6H; Figure S6E). Because the
protective effect of the mPGES-1 inhibitor was less pronounced
in Rag1/mice compared to Ptges/mice depleted of T cells,
we next examined the potential contribution of PGE2 in B cell
production of IAV specific Ab. In the serum, the levels of both
IAV-specific immunoglobulin G1 (IgG1) and IgG2a were
increased in Ptges/mice at day 11 post-IAV infection (Figures
6I and 6J). These data indicate that although T cell mediated im-
munity is essential for protection against IAV; targeted PGE2 in-
hibition enhances innate immune protection to IAV, independent
of adaptive immune components. Overall, our data suggest that
enhanced macrophage-mediated antiviral immunity through
PGE2 inhibition positively regulates both innate and adaptive
immunity to pulmonary IAV infection.
Figure 6. PGE2 Suppresses the Ag Presentation Machinery in a Type I IFN-Dependent Manner
(A and B) CD8+ T cell proliferation was measured after CFSE-labeled OT-I CD8+ T cells were cocultured for 72 hr with WT or Ptges/ BMDM (2 T cells: 1
macrophage) preloaded or not with OVA, infected or not with IAV, and in the presence or absence of the mPGES-1 inhibitor. Numbers adjacent to gates indicate
percent CD8+ T cell proliferation (CFSE dilution).
(C–F) AM from naiveWT andPtges/micewere isolated and infectedwith IAV in vitro and then adoptively transferred (i.t.) toWTmice. (D, top) Representative dot
blots depicting the frequency of IAV H-2Db-NP CD8+ T cells in the mediastinal LN of WT mice 7 days following adoptive transfer of IAV-infected WT or Ptges/
macrophages. (D, bottom) The frequency (left panel) and total number (right panel) of IAV H-2Db-NP CD8+ T cells in the mediastinal LN of WT mice 7 days
following adoptive transfer of IAV-infected WT or Ptges/ macrophages. Pulmonary viral load (E) and survival (F) were assessed 7 days after transfer.
(G and H) Survival of WT, Ptges/, or Rag1/mice infected or not with a lethal dose (150 PFU) of IAV. (G) Mice received control rat IgG or CD4+ and CD8+ T cell
depletingmonoclonal antibody (mAb) regimen (DT cells). (H)Rag1/micewere treated intraperitoneally (i.p.) with saline or with themPGES-1 inhibitor from day 1
to day 7 pi.
(I and J) Kinetics of serum anti-IAV IgG1 (I) and IgG2a (J) inWT andPtges/mice infected or not with a sublethal dose of IAVwasmeasured by ELISA. (n = 5–10; ±
SEM). Results are representative of at least three independent experiments. *p < 0.05, **p < 0.001. See also Figure S6.
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Lethal Dose of IAV Infection
Considering that Ptges/mice weremore resistant to IAV infec-
tion, we next examined whether specific inhibition of mPGES-1
would be beneficial as a treatment strategy during IAV infectionin mice. Upon infection of Ptges/ mice with a lethal dose of
IAV, the pulmonary viral load was decreased, the survival rate
increased and weight loss reduced compared to WT animals
(Figure 7A-B; Figure S7A). Furthermore, systemic administration
of PGE2 in Ptges
/ mice tended to increase their susceptibilityImmunity 40, 554–568, April 17, 2014 ª2014 Elsevier Inc. 563
Figure 7. Inhibition of PGE2 Enhances Resistance to IAV Infection
(A–F) Survival of WT, Ptges/, or Ifnar/ mice infected or not with a lethal dose (150 PFU) of IAV. (A and B) Mice were administered or not i.p. with exogenous
stable PGE2 analog 16,16-dimethyl PGE2 at day 0 and every 2 days for up to 12 days. One group of infected WT mice was also treated i.p. with the mPGES-1
inhibitor from day 1 to day 7 pi. (A) Pulmonary viral load was measured at day 3 p.i. *p < 0.05, **p < 0.001, ***p < 0.0001 (two-way ANOVA). In (B), *p < 0.05 versus
WTmice infected with IAV only (WT; IAV). (C) Infected mice were treated i.p. with saline or with the mPGES-1 inhibitor starting at different days and up to day 7 pi.
*p < 0.05, **p < 0.001 versus WT mice treated with saline. (D) Infected Ptges/ mice were administered ip. with 16,16-dimethyl PGE2 as in (A). One group of
infected Ptges/mice was also treated i.p. with EP2 antagonist and EP4 antagonist 15 min prior to PGE2 administration. Pulmonary viral load was measured at
day 3 pi. *p < 0.05, **p < 0.001 (two-way ANOVA). (E) Infected WT mice were treated i.p. with saline or with EP2 and EP4 antagonists from day 1 to day 7 p.i.
*p < 0.05. (F) Infected Ifnar/micewere treated i.p. with saline or with themPGES-1 inhibitor as in (B). (n = 5–10; ± SEM). Results are representative of three to five
independent experiments. See also Figure S7.
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mPGES-1 in WT mice from day 1 to day 7 p.i. increased protec-
tion (Figure 7A) and survival (Figure 7B; Figure S7A) to a level
similar to Ptges/ mice. The beneficial effects of the mPGES-
1 inhibitor on survival were still observed when treatment was
initiated as late as 2 or 3 days p.i. (Figure 7C; Figure S7B). Impor-
tantly, treatment with both EP2 and EP4 antagonists completely
reversed the ability of exogenous PGE2 to increase viral replica-
tion in Ptges/ mice (Figure 7D) and decreased mortality of
lethally infected WT animals (Figure 7E; Figure S7C). Finally,
the protection provided by mPGES-1 inhibition against a lethal
dose of IAV was entirely dependent on type I IFN because
Ifnar/ mice were unresponsive to treatment and succumbed
to death (Figure 7F; Figure S7D). Thus, these results demon-
strate that targeted PGE2 inhibition provides protection against
IAV and is dependent on both EP2 and EP4 receptor signaling
and a functional type I IFN response.
DISCUSSION
During IAV infection, pulmonary macrophages convert into
highly active cells and become the major source of inflammatory
cytokines and chemokines including type I IFNs, which restrict
viral replication in airway epithelial cells and dissemination.
These signals orchestrate the recruitment of inflammatory cells
in order to mount a potent antiviral immune response (Braciale564 Immunity 40, 554–568, April 17, 2014 ª2014 Elsevier Inc.et al., 2012). The data presented here provide evidence that
mPGES-1 and PGE2 play a central role in mediating susceptibil-
ity to IAV infection. IAV virions initially replicate in airway epithelial
cells and are then released in the airspace where they encounter
alveolar macrophages. Despite the fact that bronchial epithelial
cells are known to produce PGE2 (Schmidt et al., 2011), our
data demonstrate that neither the loss nor the gain of PGE2 func-
tion affected type I IFN production or viral replication directly in
this cell type. In sharp contrast, PGE2 had a strong inhibitory ef-
fect on the recruitment and antiviral properties of macrophages.
We identified two distinct and essential pathways through which
PGE2 paralyzed macrophage antiviral immunity via both EP2
and EP4 receptors: type I IFNs and apoptosis. This severely
impaired innate immunity because the IFN system directly coun-
teracts viral replication and apoptosis blocks the cellular
machinery crucial for viral amplification and dissemination. In
addition, we found that PGE2 inhibited T cell mediated immunity
to IAV infection. Thus, IAV specifically hijacks the mPGES-1/
PGE2 pathway to subvert macrophage function and suppress
both innate and adaptive immune responses in a type I IFN-
dependent manner.
The specific mechanism(s) used by the virus to increase PGE2
levels and evade host antiviral responses remain(s) unknown.
Interestingly, the nonstructural protein 1 (NS1) IAV effector pro-
tein activates PI3K, providing antiapoptotic signals (Ehrhardt
et al., 2007) and inhibits production of type I IFN throughmultiple
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This study reports PGE2-mediated suppression of macrophage
type I IFN production and apoptosis during viral infection. In
IAV-infected macrophages, PGE2 inhibited type I IFN via both
EP2 and EP4 receptors and downstream kinases PI3K-Akt and
PKA. Akt has been shown to be activated following TLR stimula-
tion and positively regulate type I IFN (Joung et al., 2011). How-
ever, it is also known that PI3K acts as a negative regulator of
TLR signaling in the later phase of TLR activation (Fukao and
Koyasu, 2003). Thus, the duration and/or magnitude of Akt acti-
vation might be critical in determining the level of type I IFN pro-
duction, and the combined action of NS1 and PGE2 on PI3K-Akt
activation might explain the inhibitory action of Akt in this
context. Alternatively, inhibition of apoptosis by PGE2 required
EP2 and PKA, but not the EP4 and PI3K-Akt pathway. This sug-
gests that the nonredundant role of EP receptors represents a
complementary strategy used by IAV to further inhibit type I
IFN and apoptosis. More studies are required to determine the
molecular basis of PGE2 induction during IAV infection and
whether viral effector molecule(s) actively modulate the level of
PGE2 and other PGs.
Although the essential role of type I IFNs in immunity to viral
infection is well established, their protective activity against bac-
terial infection is more ambiguous. In fact, it has been suggested
that type I IFN production during IAV infection is a mechanism
that sensitizes the host to bacterial superinfection. In line with
this emerging concept, the type I IFN system increases host sus-
ceptibility to Streptococcus pneumoniae (Nakamura et al., 2011;
Shahangian et al., 2009) and Mtb (Stanley et al., 2007). We also
have recently demonstrated that PGE2 enhances protection
against Mtb infection by preventing macrophage necrosis, a
form of cell death providing an exit mechanism forMtb to initiate
a new infection cycle, and inducing macrophage apoptosis
(Chen et al., 2008; Divangahi et al., 2009; Divangahi et al.,
2010). We speculate that because type I IFNs increase the path-
ogenesis ofMtb infection (Stanley et al., 2007) and PGE2 inhibits
type I IFN induction in macrophages, another independent or in-
tegrated protective mechanism of PGE2 in tuberculosis might be
the blockade of the type I IFN system. Although this could poten-
tially explain the opposing function of PGE2 in Mtb versus IAV
infection, the biology of PGE2 in the broader context of infectious
diseases, such as chronic versus acute or bacterial versus viral
infections in addition to its pathogen-specific effects remain to
be determined.
Macrophage permissiveness to IAV replication has been the
subject of recent debate (Friesenhagen et al., 2012; Lee et al.,
2012). In this study, we carefully evaluated viral replication in
macrophages from mice (BMDM and AM) and humans (THP-1
cells and primary monocyte-derived macrophages) by using
two different virus strains (Influenza A/PR/8/34 [H1N1] and Influ-
enza A/HK/1/68 [H3N2]) and two different techniques (viral load
by plaque assay in MDCK cells and intracellular staining for influ-
enza NP protein which is a direct measurement of an active IAV
replication). We found that IAV infects and productively repli-
cates in these cells and that PGE2 was the only prostanoid family
member to impair the control of viral replication in macrophages.
Whereas the biological meaning of productive IAV replication
within macrophages undoubtedly needs more scrutiny, we
anticipate that their permissiveness to IAV replication might becritical for their ability of generating Ags for activation and main-
tenance of adaptive immunity (Honke et al., 2012).
The capacity of CD4+ and CD8+ T cells to produce type 1 cyto-
kines such as IFN-g and the cytolytic activity of CD8+ T cells are
crucial mechanisms to control viral replication and to promote
clearance in the infected lungs. Consistent with the previously
published work demonstrating reduction in levels of type 1 cyto-
kines (IFN-g and IL-12) by PGE2 (Betz and Fox, 1991), we found
that PGE2 deficiency led to enhanced CD4
+ and CD8+ T cell
responses. We anticipate that at least three mechanisms
contribute to the inhibitory effect of PGE2 on T cell-mediated im-
munity. First, PGE2 reduced the number of bloodmonocytes and
their recruitment into the lungs. A recent study reported that hu-
man blood derived monocytes were highly susceptible to infec-
tion by various IAV strains, which promoted their differentiation
into DCs with enhanced Ag presentation capacity (Hou et al.,
2012). Given the important role of DCs in priming T cells, PGE2-
mediated suppression of monocyte recruitment represents a
mechanism throughwhich IAVeffectively interrupts this pathway.
Second, PGE2 disrupted the crosstalk between macrophages
and DCs by inhibiting macrophage apoptosis. Macrophages
potentially contribute to the direct priming of CD8+ T cells (Kirby
et al., 2009); however, DCs are themajor antigen-presenting cells
(APCs) implicated in this process because they can acquire viral
Ags through the uptake of apoptotic vesicles derived from IAV-
infected macrophages and cross-present these Ags to CD8+
Tcells (Albert et al., 1998). Althoughmacrophage responsiveness
to type I IFN was required for their ability to enhance CD8+ T cell
proliferation in the absence of PGE2, the direct mechanistic link
between PGE2-dependent reduction in macrophage type I IFN
production, apoptosis, and cross-priming of CD8+ T cells re-
mains to be established. Third, PGE2 directly suppressed the
intracellular processing machinery of IAV-infected APCs, as
well as their MHC class II expression impairing their capacity to
present Ags to T cells. Collectively, these findings indicate how
PGE2 can act sequentially and at multiple levels to negatively
regulate the generation of protective type 1 T cell-mediated
immunity to IAV infection.
The observation that IAV causes hyperinduction of COX-2
in human macrophages and epithelial cells has led to several
studies investigating the effect of COX-1 and/or COX-2
deficiency or inhibition during IAV infection (Lee et al., 2008;
McCarthy and Weinberg, 2012). Interestingly, COX-1 or COX-2
deficiency had contrasting effects on host response to IAV infec-
tion (Carey et al., 2005). Ptgs2/ mice exhibited lower mortality
despite elevated viral titers in the lungs and equivalent produc-
tion of PGE2 in the BAL relative toWTmice. In contrast, Ptgs1
/
mice produced less PGE2 but did not show any difference in sur-
vival and pulmonary viral load as compared to WT animals. In
another study, the nonselective COX inhibitor paracetamol
(acetaminophen) and the selective COX-2 inhibitor celecoxib
were shown to reduce lung immunopathology following IAV
infection without having any effect on viral clearance or genera-
tion of adaptive immunity (Lauder et al., 2011). We envision that
the reasoning behind these controversial studies is the fact that
inhibition of COX enzymatic activity leads to the suppression of
all PGs and their respective derivatives. These PGs have distinct
properties and therefore are likely to have diverse roles during
viral infection. For instance, treatment with the PGD2 derivativeImmunity 40, 554–568, April 17, 2014 ª2014 Elsevier Inc. 565
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viral load, and protects mice against lethal IAV infection (Cloutier
et al., 2012). Our study, alternatively, demonstrated that inhibi-
tion of PGE2 per se decreased pulmonary viral load, improved
lung function, and enhanced survival following IAV infection.
This highlights the importance of considering PGs as a group
of individual lipid mediators with distinct functions in antiviral
immunity.
Despite the worldwide application of vaccination and other
antiviral interventions, IAV infection remains a persistent threat
to human health especially due to the emergence of novel
pandemic strains. Following the increased popularity of aspirin
during the 1918 pandemic, one century of NSAID usage has
taught us that inhibition of COX and subsequently all PGs might
have beneficial effects for the management of IAV symptoms. It
is also important to consider that aspirin overuse might have
increased the severity of the 1918 IAV, and the use of salicylates
in children with IAV or other viral illnesses has also been associ-
ated with mortality due to the development of Reye’s syndrome
(Starko, 2009). However, we herein report that the selective inhi-
bition of PGE2 using a nonsalicylate compound that does not
inhibit COX activity enhances immunity and protects against
IAV infection. Preclinical studies in animals have identified a
number of mPGES-1 inhibitory compounds that are orally active
at relatively high doses in animal models of inflammatory disease
and lead to the development of selective humanmPGES-1 inhib-
itors such as MF63 (Xu et al., 2008). Thus, specific suppression
of PGE2 represents a feasible and immediate therapeutic avenue
for the treatment and prevention of influenza and potentially
other viral infections.
EXPERIMENTAL PROCEDURES
See the Supplemental Information for details.
Mice
Six- to ten-week-old C57BL/6 mice, OT-I T cell antigen receptor-transgenic
mice (Taconic 4175) and Rag1/ mice (Jax 002096) were from the Jackson
Laboratory. Ptges/mice (Chen et al., 2008; Divangahi et al., 2009; Divangahi
et al., 2010) (backcrossed to the C57BL/6 background, kindly provided by
B. Koller, University of North Carolina) and Ifnar/ mice on C57BL/6 back-
ground (kindly provided by J.H. Fritz) were bred at McGill University. Experi-
ments were conducted in accordance with the guidelines of animal research
ethics board of McGill University.
Viruses and Infections
All in vivo and in vitro infections were performed with mouse-adapted IAV
H1N1 strain A/Puerto Rico/8/34 (kindly provided by J.A. McCullers) except
for in vitro infection of human cells that were performed with the clinical strain
H3N2 A/Hong-Kong/1/68 (kindly provided by S. Qureshi). UV IAV for in vitro
stimulation was generated with the H1N1 strain. In vivo infections were
performed intranasally (25 ml), and the lethal dose of IAV H1N1 used for survival
experiments was 150–200 PFU unless indicated otherwise, whereas the
sublethal dose was 50 PFU. Viruses were propagated and isolated from
Madin-Darby canine kidney (MDCK) cells and titrated with standard plaque
assay in MDCK cells (Gaush and Smith, 1968).
Flow Cytometry Analysis
Single-cell suspensions obtained from BAL and collagenase- and DNase-
treated lungs; blood or LN were stained with different combinations of Abs
(Divangahi et al., 2009; Divangahi et al., 2010). Flow cytometry was performed
with BD LSR II (BDBiosciences) and analysis was performed with FlowJo Soft-
ware (Tree Star).566 Immunity 40, 554–568, April 17, 2014 ª2014 Elsevier Inc.Quantitative RT-PCR
Total RNA was isolated from mouse and human cells using TRIzol reagent
(Invitrogen) and processed with Moloney murine leukemia virus reverse
transcriptase (QuantiTect Reverse Transcription Kit, QIAGEN) for mRNA anal-
ysis by qRT-PCR with Bio-Rad Icycler Software (Bio-Rad Laboratories).
Expression of mRNA was shown as fold induction of infected cells relative
to uninfected or unstimulated cells of the same genotype unless stated
otherwise.
Cell Death Assays
For in vitro experiments, apoptosis was measured by the cell-death detection
ELISAPLUS (Roche Applied Science) (Divangahi et al., 2009; Divangahi et al.,
2010). The amount of apoptotic bleb formation was also measured with the
Apoptotic Blebs Assay Kit (Cayman Chemical). For in vivo infections, necrosis
and apoptosis were quantified with the Apoptosis Detection Kit I (BD Biosci-
ences) and analyzed by flow cytometry.
Adoptive Transfer Models of Infection
AM were collected from the BAL of naive WT and Ptges/ mice and sus-
pended macrophages were infected for 2 hr in vitro with 0.5 (Figure 3F) or 5
MOI (Figure 6C) of IAV H1N1 A/PR/8/34. Free viruses were then removed by
three washes with PBS, each followed by centrifugation for 10 min at 200g
and 4C. Cells were resuspended in PBS at a density of 0.5 3 106 cells per
40 ml and then transferred by the i.t. route into naive Rag1/ mice or WT
mice (Divangahi et al., 2009; Divangahi et al., 2010). For BMDMadoptive trans-
fer (Figure 3I), 1 3 106 uninfected WT or Ptges/ cells were transferred (i.t.)
into naive WT mice, which were infected i.n. with IAV H1N1 A/PR/8/34 (600
PFU) 2 hr later.
Statistics
Data was analyzed with PRISM 6.0 Software (GraphPad Software). Student’s
t test and two-way ANOVA (when indicated) were performed except for sur-
vival experiments where data was analyzed by the log rank test. Differences
were considered significant at p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
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